Nosocomial Pseudomonas putida Bacteremia: High Rates of Carbapenem Resistance and Mortality

Seong Eun Kim; Seong-Hwan Park; Hyun Bum Park; Kyung-Hwa Park; Su-Hyun Kim; Sook-In Jung; Jong-Hee Shin; Hee-Chang Jang; Seung Ji Kang

doi:10.4068/cmj.2012.48.2.91

Journal List > Chonnam Med J > v.48(2) > 1074880

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim, Park, Park, Park, Kim, Jung, Shin, Jang, and Kang: Nosocomial Pseudomonas putida Bacteremia: High Rates of Carbapenem Resistance and Mortality

Original Article

Infection and Immunology

Chonnam Medical Journal

Chonnam Medical Journal 2012; 48(2): 91-95.

Published online: 24 August 2012

DOI: https://doi.org/10.4068/cmj.2012.48.2.91

Nosocomial Pseudomonas putida Bacteremia: High Rates of Carbapenem Resistance and Mortality

Seong Eun Kim^#, Seong-Hwan Park^#, Hyun Bum Park, Kyung-Hwa Park, Su-Hyun Kim³, Sook-In Jung, Jong-Hee Shin¹, Hee-Chang Jang², Seung Ji Kang

Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.

1Department of Laboratory Medicine, Chonnam National University Medical School, Gwangju, Korea.

2Department of Internal Medicine, Chonnam National University Medical School, Hwasun, Korea.

3Department of Laboratory Medicine, Chonnam National University Medical School, Hwasun, Korea.

Corresponding Author: Seung Ji Kang. Department of Internal Medicine, Chonnam National University Medical School, 671 Jebong-no, Dong-gu, Gwangju 501-757, Korea. TEL: +82-62-220-6296, FAX: +82-62-225-8578, sseungi@gmail.com

Equal contributor:

#Seong Eun Kim and Seong-Hwan Park contributed equally to this work.

Received 2 August 2012 Revised 9 August 2012 Accepted 13 August 2012

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Previously, Pseudomonas putida was considered a low-virulence pathogen and was recognized as a rare cause of bacteremia. Recently, however, multidrug-resistant and carbapenem-resistant P. putida isolates have emerged, causing difficult-to-treat nosocomial infections in seriously ill patients. Currently, the outcome of multidrug-resistant or carbapenem-resistant P. putida bacteremia remains uncertain. Here, we report 18 cases of P. putida bacteremia with high rates of carbapenem resistance and mortality. From January 2005 through December 2011, all cases of nosocomial P. putida bacteremia were identified and analyzed at Chonnam National University Hospital and Chonnam National University Hwasun Hospital. Electronic medical records were reviewed retrospectively. Four (22%) and five (23%) of 18 P. putida isolates were resistant to imipenem and meropenem, respectively. Common primary infection sites were central venous catheter (7, 39%), pneumonia (5, 28%), and cholangitis (2, 11%). Fourteen (78%) patients had indwelling devices related to the primary site of infection. The 30-day mortality rate was 39% (7/18): 40% (2/5) in patients with carbapenem-resistant P. putida bacteremia vs. 38% (5/13) in patients with carbapenem-susceptible P. putida bacteremia. Nosocomial P. putida bacteremia showed high resistance rates to most potent β-lactams and carbapenems and was associated with high mortality rates.

Keywords: Pseudomonas putid, Carbapenems, Drug resistance

INTRODUCTION

Pseudomonas putida, of the fluorescent group of Pseudomonas species, as well as other nonfermenting Gram-negative organisms frequently found in the environment (e.g., Acinetobacter, Burkholderia, and Stenotrophomonas species), were previously thought to be of low pathogenicity.1 Over the last three decades, however, these have been increasingly encountered as significant human pathogens. Because P. putida can colonize moist and inanimate hospital surfaces, it causes nosocomial infections, especially in immunocompromised patients and in patients possessing medical devices or catheters.2,3 Outbreaks of bloodstream infection associated with contaminated fluids have also been reported.4-7

Despite the fact that this organism causes healthcare-related infections, clinical data on P. putida infections are lacking owing to the rarity, relatively lower virulence, and higher antimicrobial susceptibility of P. putida compared with other Pseudomonas species, especially Pseudomonas aeruginosa.2,8-10 However, recently, the emergence of multi-drug-resistant (MDR) and carbapenem-resistant P. putida has become a cause for concern.11-15 The outcome of MDR P. putida bacteremia has not been extensively investigated. Here, we report carbapenem resistance rates and outcomes of 18 P. putida bacteremia cases treated in a tertiary care hospital.

MATERIALS AND METHODS

1. Study design and patient selection

Patients with P. putida bacteremia from January 2005 to December 2011 at Chonnam National University Hospital (1,000 beds) and Chonnam National University Hwasun Hospital (700 beds) were identified through a review of the clinical microbiology laboratory records. Only the first bacteremic episode for each patient was included in the analysis. Nosocomial bacteremia was defined as the isolation of one or more positive blood cultures in a patient occurring 48 hours after admission. Data collected from electronic medical records included age, gender, underlying disease, comorbid conditions, prior receipt of any type of antibiotics within the previous 30 days, primary sites of infection, antibiotic regimens and duration, and 30-day mortality. The following comorbid conditions were also documented at the time of infection: neutropenia, prior surgery within the previous 3 months, and presence of medical devices or catheters.

2. Microbiological tests

The VITEK II automated system (bioMérieux Inc., Marcy l'Etoile, France) provided microbiological identification and antimicrobial susceptibility testing by use of a standard identification card. Strains showing "intermediate" antimicrobial susceptibility testing were considered resistant. The antimicrobial agents tested included piperacillin, piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, imipenem, meropenem, tobramycin, amikacin, levofloxacin, ciprofloxacin, and colistimethate. An MDR strain was defined as a strain resistant to three or more of the five categorized classes.16

RESULTS

1. Clinical features and outcomes in patients with P. putida bacteremia

During the study period, 24 patients with nosocomial P. putida bacteremia were identified. Among these, five cases of P. putida bacteremia were clustered and removed from this report. In addition, one more case was excluded because the P. putida blood isolate was considered as contamination. The patient had no systemic inflammatory signs when the blood was obtained and the P. putida was isolated in only one pair of blood cultures. The clinical features and outcomes of the remaining 18 patients with P. putida bacteremia are summarized in Table 1. The mean age (±standard deviation) of the patients was 56±20 years. Solid tumor was the most common underlying disease (n=8, 44%), followed by traumatic intracranial hemorrhage (n=2, 11%). Eight patients (44%) had undergone an operation within the previous 3 months, and two patients (11%) had experienced neutropenia. Sixteen patients (89%) had been administered antibiotics within 1 month prior to P. putida bacteremia. The most common primary site of infection was the central venous catheter (n=7, 39%), followed by ventilator-associated pneumonia (n=4, 22%) and the biliary tract (n=2, 11%). Fourteen cases (77%) were device-related infections (central venous catheter 7, endotracheal tube 4, biliary stent 1, indwelling urinary catheter 1). Polymicrobial infection was found in five (28%) cases.

The 30-day mortality rate was 39% (7/18): 40% (2/5) in patients with carbapenem-resistant P. putida bacteremia vs. 38% (5/13) in patients with carbapenem-susceptible P. putida bacteremia. Three of 7 patients who died (43%) had received inappropriate antibiotics compared with 2 of 11 survivors (19%; p=0.326).

2. Antibiotic resistance in P. putida nosocomial isolates

The rate of resistance of 18 P. putida blood isolates to antibiotics is shown in Table 2. Four (22%) and five (28%) isolates of the 18 P. putida isolates were resistant to imipenem and meropenem. MDR strains were found in 28% of P. putida isolates. None of the P. putida isolates was resistant to colistimethate.

DISCUSSION

Infections caused by P. putida are relatively rare and are generally restricted to immunocompromised patients and patients with invasive medical devices in place.8 Excluding pediatric and outbreak cases due to transfusion of contaminated blood or fluid, P. putida bacteremia is rarely reported. To date, Anaissie et al. reported six oncology patients with P. putida bacteremia17 and Yang et al. reported eight cases in Taiwan.18 Recently, five cases of P. putida bacteremia were reported in Japan.2 This study likely contains the largest number of P. putida bacteremia cases in the literature to date.

Among the 18 cases reported here, 77% were device-related infections, and 56% of the cases were in an immunocompromised state (e.g., solid tumor, hematologic malignancy, liver cirrhosis). The clinical features present in our study were similar to those seen in previous studies.2,8

In previous reports, clinical isolates of P. putida showed high susceptibility to various antibiotics. For example, Fass et al. reported 100% susceptibility of 15 P. putida clinical isolates to ciprofloxacin and tobramycin and 87% to imipenem and piperacillin/tazobactam.19 However, carbapenem-resistant P. putida isolates from the urinary tract, tracheal aspiration, and areas other than blood are increasingly being reported.11,20 This carbapenem-resistance mechanism was known to be related with metallo-β-lactamase (MBL) production. In Korea, 12 imipenem-resistant isolates of Pseudomonas species other than P. aeruginosa were collected by the Korean Nationwide Surveillance of Antimicrobial Resistance (KONSAR) program in 2005. Among them, eight (67%) isolates were MBL-producing pathogens, all of which were identified as P. putida.21 In our study, 4 (22%) and 5 (28%) isolates of the 18 P. putida isolates were resistant to imipenem and meropenem. In the same period, 171 P. aeruginosa blood isolates were collected in the same hospitals (data not shown) and the antibiotics susceptibility was compared with that of the 18 P. putida isolates. The carbapenem-resistance rates did not differ significantly from those of P. aeruginosa blood isolates (28% vs. 23%; p=0.771). The resistance rate of other antibiotics was also similar (data not shown). However the aztreonam resistance rate of P. putida was significantly higher than that of P. aeruginosa (72% vs. 34%, p=0.001). These findings suggest that multidrug and carbapenem resistance is prevalent not only in P. aeruginosa bacteremia but also in P. putida bacteremia.

Unlike the well-known P. aeruginosa isolates, P. putida isolates were generally considered to have a low level of virulence and to be of little clinical significance.10 A brief review of the literature revealed that the prognosis of P. putida bacteremia has been shown to be good, with 26 (93%) of 28 cases being cured.2 However, in contrast to previous reports, the mortality rate in our patients with P. putida bacteremia was high. There are two possible explanations for this. The first is the higher rate of pneumonia as the primary site of infection in this study. The mortality rate in patients with pneumonia was high (40%; 2 of 5 patients) in this study, whereas previous studies reported that only 13% of the patients with P. putida infection had pneumonia.8 The second is inadequate antimicrobial therapy in seriously ill patients. Three of 7 patients who died (43%) had received inappropriate antibiotics, compared with 2 of 11 survivors (19%; p=0.326). The higher rate of multi-drug and carbapenem resistance (28%) is presumed to affect the rate of inappropriate antibiotic therapy and high mortality, but further study with more cases is required to verify this relationship.

Our study had several limitations. First, organism identification was performed by using an automated system and was not confirmed by genotypic-based methods such as 16S rRNA gene sequencing. However, according to Jacquier et al., eight of nine P. putida isolates confirmed by 16S rRNA gene sequencing were identified accurately at the species level by using the VITEK II system and there was no misidentification.22 In addition, previous studies have used automated systems for the identification of P. putida.2,8 Thus, the VITEK II automated system is considered an acceptable tool for the identification of this organism. Second, the possibility of outbreak was excluded only by temporal relations of isolates, not by epidemiological tools such as pulsed-field gel electrophoresis. However, because there were no spatial or temporal relations between cases, we suggest that there is little possibility that outbreak cases were included in this study.

In conclusion, nosocomial infections of P. putida are highly resistant to the most potent β-lactams and carbapenems and can cause significant morbidity and mortality in infected patients. Thus, it is necessary to be aware of the fatality of nosocomial P. putida bacteremia and to consider the early initiation of appropriate antibiotic regimens.

Figures and Tables

TABLE 1

Clinical characteristics and outcomes of 18 patients with P. putida nosocomial bacteremia

^*Transferred from other hospitals, admitted more than 48hours before the transfer,^†Duration from admission to P.putida isolation in blood, ^‡Not appraisable, this strain was resistant to meropenem but susceptible to imipenem. ICU: intensive care unit, MDR: multidrug resistance, ICH: intracranial hemorrhage, CVC: central venous catheter, Y: yes, N: no, Pip-Tazo: Piperacillin/tazobactam, d/t: due to, P. aeruginosa: Pseudomonas aeruginosa, ALL: acute lymphoblastic leukemia, VAP: ventilator associated pneumonia, RUL: right upper lobe, C. freundii: Citrobacter freundii, UTI: urinary tract infection, IHD: ischemic heart disease, HTN: hypertension, DM: diabetes mellitus, SMA: superior mesenteric artery.

TABLE 2

Antibiotics susceptibilities of 18 P. putida blood isolates

^*Strains showing "intermediate" antimicrobial susceptibility testing were considered resistant. Pip-Tazo: Piperacillin/tazobactam, R: resistance, I: intermediate, S: susceptible.

References

1. Von Graevenitz A, Weinstein J. Pathogenic significance of Pseudomonas fluorescens and Pseudomonas putida. Yale J Biol Med. 1971. 44:265–273.

2. Yoshino Y, Kitazawa T, Kamimura M, Tatsuno K, Ota Y, Yotsuyanagi H. Pseudomonas putida bacteremia in adult patients: five case reports and a review of the literature. J Infect Chemother. 2011. 17:278–282.

3. Martino R, Martínez C, Pericas R, Salazar R, Solá C, Brunet S, et al. Bacteremia due to glucose non-fermenting gram-negative bacilli in patients with hematological neoplasias and solid tumors. Eur J Clin Microbiol Infect Dis. 1996. 15:610–615.

4. Souza Dias MB, Habert AB, Borrasca V, Stempliuk V, Ciolli A, Araújo MR, et al. Salvage of long-term central venous catheters during an outbreak of Pseudomonas putida and Stenotrophomonas maltophilia infections associated with contaminated heparin catheter-lock solution. Infect Control Hosp Epidemiol. 2008. 29:125–130.

5. Perz JF, Craig AS, Stratton CW, Bodner SJ, Phillips WE Jr, Schaffner W. Pseudomonas putida septicemia in a special care nursery due to contaminated flush solutions prepared in a hospital pharmacy. J Clin Microbiol. 2005. 43:5316–5318.

6. Torii K, Noda Y, Miyazaki Y, Ohta M. An unusual outbreak of infusion-related bacteremia in a gastrointestinal disease ward. Jpn J Infect Dis. 2003. 56:177–178.

7. Oğuz SS, Unlü S, Saygan S, Dilli D, Erdoğan B, Dilmen U. Rapid control of an outbreak of Pseudomonas putida in a tertiary neonatal intensive care unit. J Hosp Infect. 2010. 76:361–362.

8. Carpenter RJ, Hartzell JD, Forsberg JA, Babel BS, Ganesan A. Pseudomonas putida war wound infection in a US Marine: a case report and review of the literature. J Infect. 2008. 56:234–240.

9. Korcova J, Koprnova J, Krcmery V. Bacteraemia due to Pseudomonas putida and other Pseudomonas non-aeruginosa in children. J Infect. 2005. 51:81.

10. Blazevic DJ, Koepcke MH, Matsen JM. Incidence and identification of Pseudomonas fluorescens and Pseudomonas putida in the clinical laboratory. Appl Microbiol. 1973. 25:107–110.

11. Almuzara M, Radice M, de Gárate N, Kossman A, Cuirolo A, Santella G, et al. VIM-2-producing Pseudomonas putida, Buenos Aires. Emerg Infect Dis. 2007. 13:668–669.

12. Treviño M, Moldes L, Hernández M, Martínez-Lamas L, García-Riestra C, Regueiro BJ. Nosocomial infection by VIM-2 metallo-beta-lactamase-producing Pseudomonas putida. J Med Microbiol. 2010. 59:853–855.

13. Kumita W, Saito R, Sato K, Ode T, Moriya K, Koike K, et al. Molecular characterizations of carbapenem and ciprofloxacin resistance in clinical isolates of Pseudomonas putida. J Infect Chemother. 2009. 15:6–12.

14. Poirel L, Yakupoğullari Y, Kizirgil A, Dogukan M, Nordmann P. VIM-5 metallo-beta-lactamase-producing Pseudomonas putida from Turkey. Int J Antimicrob Agents. 2009. 33:287.

15. Bennett JW, Herrera ML, Lewis JS 2nd, Wickes BW, Jorgensen JH. KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient. Antimicrob Agents Chemother. 2009. 53:292–294.

16. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis. 2008. 46:1121–1122.

17. Anaissie E, Fainstein V, Miller P, Kassamali H, Pitlik S, Bodey GP, et al. Pseudomonas putida. Newly recognized pathogen in patients with cancer. Am J Med. 1987. 82:1191–1194.

18. Yang CH, Young T, Peng MY, Weng MC. Clinical spectrum of Pseudomonas putida infection. J Formos Med Assoc. 1996. 95:754–761.

19. Fass RJ, Barnishan J, Solomon MC, Ayers LW. In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli. Antimicrob Agents Chemother. 1996. 40:1412–1418.

20. Bogaerts P, Huang TD, Rodriguez-Villalobos H, Bauraing C, Deplano A, Struelens MJ, et al. Nosocomial infections caused by multidrug-resistant Pseudomonas putida isolates producing VIM-2 and VIM-4 metallo-beta-lactamases. J Antimicrob Chemother. 2008. 61:749–751.

21. Lee K, Park AJ, Kim MY, Lee HJ, Cho JH, Kang JO, et al. Metallo-beta-lactamase-producing Pseudomonas spp. in Korea: high prevalence of isolates with VIM-2 type and emergence of isolates with IMP-1 type. Yonsei Med J. 2009. 50:335–339.

22. Jacquier H, Carbonnelle E, Corvec S, Illiaquer M, Le Monnier A, Bille E, et al. Revisited distribution of nonfermenting Gram-negative bacilli clinical isolates. Eur J Clin Microbiol Infect Dis. 2011. 30:1579–1586.

TOOLS

Similar articles